We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A picture of Kate Robinson

Kate Robinson profile page

Science Editor

 at Technology Networks


Kate graduated from Sheffield Hallam University with a bachelor's degree in biomedical sciences in 2020. During her studies, she developed a passion for science communication and after graduating, began a science blog in order to continue writing about trending science news and topics of interest. She joined the editorial team at Technology Networks in 2021. In her role as science editor Kate supports the publication’s in-house writers, produces scientific content across all communities and works closely with the managing editor to help coordinate commissioned pieces.


Education


Sheffield Hallam University  


Accreditations


Biomedical Science BSc (Hons) recognised by Sheffield Hallam University


Areas of Expertise



Got a Question for Kate Robinson?


Get in touch using the contact form linked here and we’ll get back to you shortly.



Published Content
Total: 88
Exploiting Natural Disease Resistance in Mammals To Advance Drug Development content piece image
Industry Insight

Exploiting Natural Disease Resistance in Mammals To Advance Drug Development

We spoke to Ashley Zehnder, CEO and founder of Fauna Bio to learn more about how the company seeks to find new treatments for diseases such as cancer and Alzheimer’s, by exploiting natural disease resistance in mammals.
The Ethics and Safety of COVID-19 Vaccine Passports content piece image
Article

The Ethics and Safety of COVID-19 Vaccine Passports

We spoke to Tasnime Osama, honorary clinical research fellow at Imperial College London to learn about the ethical considerations surrounding vaccine passports and how ethical hacking could improve their security.
What Does the Fourth Industrial Revolution Mean for Research? content piece image
Industry Insight

What Does the Fourth Industrial Revolution Mean for Research?

LabVantage Solutions, Inc., a provider of laboratory informatics software solutions, has signaled a turn towards the future with its appointment of digital transformation veteran Mikael Hagstroem as its new chief executive officer. We spoke to Mikael to find out more.
Detecting Residual Cancer Using Whole-Genome Sequencing and Artificial Intelligence content piece image
Industry Insight

Detecting Residual Cancer Using Whole-Genome Sequencing and Artificial Intelligence

When a tumor is surgically removed, small amounts of residual cancer can remain at a level that is undetectable with current imaging or blood-based approaches. In this interview, Technology Networks spoke with Asaf Zviran, co-founder and CEO of C2i Genomics to find out more about the company’s C2-Intelligence Platform for the detection of trace amounts of cancer.
Opinionated Science Episode 24: Mayan Bones, Boozy Brains and Baboon Logic content piece image
Podcast

Opinionated Science Episode 24: Mayan Bones, Boozy Brains and Baboon Logic

In this episode, the TN team review what happens in the brain when we drink alcohol, find out how to use baboons and grapes to make discoveries about logic processing and unearth the rise-and-fall life story of an ancient Mayan.
The Development of Natural Killer Cells for Solid Tumor Treatment content piece image
Industry Insight

The Development of Natural Killer Cells for Solid Tumor Treatment

We interviewed Jan Davidson MD., PhD., the newly appointed chief medical officer at Wugen to learn more about the company's agreement with Washington University to further their Memory NK Cell program.
Accelerating Scientific Study With Scalable Single-Cell Sequencing content piece image
Industry Insight

Accelerating Scientific Study With Scalable Single-Cell Sequencing

Technology Networks recently interviewed Alex Rosenberg, co-founder and CEO of Parse Biosciences to learn more about the company and its novel approach to single-cell sequencing.
Targeting the Dopamine Receptor Pathway To Treat AML content piece image
Article

Targeting the Dopamine Receptor Pathway To Treat AML

Technology Networks recently interviewed Prof. Mick Bhatia, from McMaster University, to learn more about his research focused on the role of abnormal dopamine receptor pathway activation in adult patients with acute myeloid leukemia (AML).
Advertisement